Consultant Medical Oncologist
A consultant Medical Oncologist with over 30 years’ experience, and co-founder of the Leaders in Oncology Care Clinic.
As one of its four founder partners, Dr Slevin has played a leading role in developing the state-of-the-art systems and software at LOC. He is also a founder member of "Doctors for Reform", a group of consultants working to improve the NHS.
Dr Slevin has been Chair of several medical research committees including the Medical Research Council “Cell Board”,British Psychosocial Oncology Group And a grant awarding body for cancer research. He acted as an advisor to the Department of Trade and Industry on computing and oncology.Dr Slevin’s research focused on optimising the use of cancer chemotherapy to understand why some patients do better than others through monitoring pharmacology in individual patients. His research has also involved mathematical modelling of cancer treatment and psychosocial oncology to understand how people cope with cancer diagnoses. He sat on 5 editorial boards and has authored or co-authored almost 200 papers in medical journals, such as the Lancet and British Medical Journal, written two books, edited three others, and has contributed 17 chapters in textbooks.
Dr Slevin graduated from the University of Cape Town and subsequently worked for four years at the world-famous Groote Schuur Hospital before coming to the UK. He spent 30 years in the Department of Medical Oncology at London's St Bartholomew's.
In 1985 he co-founded CancerBACUP, the UK's leading charity providing cancer information and support to cancer patients and their families. He was the organisations chairman for 21 years. In May 2008, following the merger of CancerBACUP with Macmillan, Dr Slevin became a trustee of Macmillan Cancer Support. He was also a trustee of the Cancer Research Campaign for 5 years.
Services provided to HCA
Dr Slevin provides medical advisory services to HCA. In his role, Dr Slevin leads interactions with hospital medical staff and the hospital leadership team to assist the hospital by providing medical advice and promote high quality, cost effective care.
In his role, he contributes to the strategy, policies and decision making regarding oncology treatments and advises HCA to ensure that care provided within the facility is appropriate and efficient. In his role, Dr Slevin advises on initiatives to drive clinical standards by providing professional advice on clinical governance matters and ensuring the adoption of those by colleagues in the oncology area.
In addition, he works with medical insurance companies, GPs, other relevant local NHS contacts, and patients to educate and advise on relevant clinical updates to treatments in oncology available in the facility. Furthermore, he advises on the accuracy of literature that may be published regarding relevant services. He will also advise on how to make the patient referral smooth to reduce stress and anxiety for patients.
Dr Slevin has specific responsibility for supervising the information technology for medical oncology, which he was involved in setting up when the LOC was established. This involves optimising and supervising implementation and use of software. The LOC became the first medical clinic to run a paperless system in the UK. He has developed detailed electronic audit process of the treatments that are given at the LOC to ensure that the highest possible standards are maintained at all times. Dr Slevin also sits on the management board responsible for supervising LOC and is involved in its day to day management.
All services provided under this agreement are charged to HCA on an hourly basis as a rate of £274 per hour. This figure has been audited by market experts LaingBuisson and is considered fair market value.
All services provided under this agreement are charged to HCA UK. From January to December 2017, the total charge was £100,000. for Dr Maurice L Slevin.
HCA requires the doctors that advise us to attest that if they also practice in the NHS that they are not compromising their NHS commitments.
The information disclosed on this page in accordance with the Private Healthcare Market Investigation Order 2014 is true and accurate to the best of HCA’s knowledge and belief.